TrialBiomolecules & biomedicine2026
Circulating tumor DNA as a prognostic biomarker in metastatic colorectal cancer: Post-hoc analysis of treatment response and survival outcomes in the ALTER-C-002 study.
Yue Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.